|
Dear VIJAY PITHADIA:
Your September 2013 digital issue of P&T journal is available.
This issue contains:
Feature articles
- Prescription Drug Abuse Hits Hospitals Hard
Tighter Federal Steps Aim to Deflate Crisis
Hospitals and their pharmacy departments are now at the epicenter of the prescription drug-abuse tsunami. The Obama administration is using regulatory agencies in an to attempt to crack down on physician-run "pill mills" and the pharmacies that support them.
- Identifying Knowledge Gaps in the Labeling of Medications For Geriatric Patients
The authors found that two-thirds of drugs approved by the FDA in recent years lacked adequate efficacy and safety information for use in older patients. With an expected doubling of the elderly population by 2040, it is time for pharmaceutical manufacturers to incorporate more robust prescribing information into their product labels of drugs used in this patient population.
- Role of Pharmacogenomic Biomarkers in Predicting And Improving Drug Response
Part 1: The Clinical Significance of Pharmacogenetic Variants
As genotyping and genetic testing become more sophisticated, accessible, and cost-effective, these tools hold great promise for predicting and improving responses to medications.
- CONTROVERSIES IN PRACTICE
Prostate Cancer Risk and Omega-3 Fatty Acid Intake From Fish Oil
A Closer Look at Media Messages Versus Research Findings
Although fish and fish oil supplements have been touted for their many benefits, especially in the treatment of cardiovascular disease, recent headlines have suggested that they might be linked to an increased risk of prostate cancer. P&T takes a closer look behind the mixed messages.
Plus our regular columns: Medication Errors, Prescription: Washington, New Drugs/Drug News/New Medical Devices, Pharmaceutical Approval Update, and Drug Forecast.
Click here to begin reading the current issue.
Click here to subscribe to P&T journal
Call for Papers
P&T is accepting article submissions from its readers. We welcome a wide variety of manuscripts, including drug class reviews, disease state management reviews, pharmacoeconomic analyses, outcomes research evaluations, DUEs, P&T committee experiences, commentaries, book reviews, and letters to the editor. Please contact Sonja Sherritze, via phone (267-685-2779) or mobile 267-907-5642) or e-mail (ssherritze@medimedia.com) for more information.
We hope you enjoy this issue of P&T. If you have any comments or questions about this digital format, please send an e-mail to me at tberberabe@medimedia.com
Tony Berberabe, MPH
Senior Web Editor |
Posts
